Evidence map›Paper›PMID 42498916›Full record

ArticleImmunologic research2026

Bone marrow SUVmax on

Hao Xiong, Huitao Zhang, Wenting Tie, Yongqiang Wang, Yijun Dong, Li Zhang, Yanhong Li, Jun Bai, Jinping Zhang, Yuxian Wang and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Immunologic research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hao XiongDepartment of Hematology, The Second Hospital of Lanzhou University, Lanzhou, China.
Huitao ZhangGeneral Practice Department, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Wenting TieDepartment of Endocrinology, The Second Hospital of Lanzhou University, Lanzhou, China.
Yongqiang WangDepartment of Hematology, Jiugang Hospital, Jiuquan, China.
Yijun DongThe Second Clinical Medical College of Lanzhou University, Lanzhou, China.
Li ZhangDepartment of Hematology, The Second Hospital of Lanzhou University, Lanzhou, China.
Yanhong LiDepartment of Hematology, The Second Hospital of Lanzhou University, Lanzhou, China.
Jun BaiDepartment of Hematology, The Second Hospital of Lanzhou University, Lanzhou, China.
Jinping ZhangDepartment of Hematology, The Second Hospital of Lanzhou University, Lanzhou, China.
Yuxian WangDepartment of Hematology, The Second Hospital of Lanzhou University, Lanzhou, China.
Liansheng ZhangDepartment of Hematology, The Second Hospital of Lanzhou University, Lanzhou, China. zhanglsh@lzu.edu.cn.
Lijuan LiDepartment of Hematology, The Second Hospital of Lanzhou University, Lanzhou, China. doctorljuan@sina.com.ORCID http://orcid.org/0009-0002-5983-677X

Funding

the Fundamental Research Funds for the Central Universities lzujbky-2024-ou19the National Natural Science Foundation of China 82360029the Science and Technology Program of Luzhou City 2025JYJ048
6 · The paper itself

Abstract

Disorder of the immune microenvironment plays an important role in the occurrence and development of multiple myeloma in patients. While bone marrow SUVmax on

Indexed as

Bone MarrowFluorodeoxyglucose F18Multiple MyelomaPositron Emission Tomography Computed TomographyT-Lymphocytes, RegulatoryAgedCytokinesFemaleHumansMaleMiddle AgedRadiopharmaceuticalsTumor MicroenvironmentCytokinesFluorodeoxyglucose F18RadiopharmaceuticalsCytokinesGlucose metabolismImmune cellMultiple myeloma

Identifiers

PMID42498916

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.